ArticleCancer reports (Hoboken, N.J.)2025
Bioinformatics Analysis Identifies Lipid Droplet-Associated Gene Signatures as Promising Prognostic and Diagnostic Models for Endometrial Cancer.
Article in Cancer reports (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Alterations in lipid metabolism and blood profile in gynecological cancers - potential strategies in diagnosis and treatment.Frontiers in physiology · 2026Review
- Bioinformatics Analysis Identifies Lipid Droplet-Associated Gene Signatures as Promising Prognostic and Diagnostic Models for Endometrial Cancer.Cancer reports (Hoboken, N.J.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEffective diagnostic and prognostic tools are critical for early detection and improved outcomes in endometrial cancer (EC). Although metabolic dysregulation plays a key role in EC pathogenesis, the clinical relevance of lipid droplet-associated genes (LDAGs) remains largely unexplored. This study aims to establish LDAG-based gene signatures with strong diagnostic and prognostic potential in EC.
aimsTo identify LDAG signatures with prognostic and diagnostic utility in EC. METHODS AND
resultsA curated set of LDAGs was systematically analyzed across publicly available EC datasets to identify differentially expressed LDAGs (DE-LDAGs). Survival-associated DE-LDAGs were then identified using univariate Cox regression. A four-gene prognostic model was developed through LASSO-based feature selection followed by multivariate Cox regression and validated using Kaplan-Meier survival and time-dependent receiver operating characteristic (ROC) analyses. From the same pool of survival-associated DE-LDAGs, a six-gene diagnostic model was constructed using LASSO, ROC analysis, and logistic regression. Model performance was evaluated using ROC curves and support vector machine (SVM) classification. Functional enrichment and protein-protein interaction (PPI) network analyses were conducted to assess the biological relevance of the identified genes. Our results demonstrate that the four-gene prognostic model (LMLN, LMO3, PRKAA2, and RAB10) stratified EC patients into high- and low-risk groups with significantly different survival outcomes (p < 0.05; time-dependent AUC > 0.70). The six-gene diagnostic model (AIFM2, ABCG1, LIPG, DGAT2, LPCAT1, and VCP) demonstrated near-perfect classification of tumor versus normal tissues (AUC ≈0.99 in ROC analysis; 99.8% accuracy in SVM analysis). Functional enrichment linked DE-LDAGs to lipid metabolism, ER stress response, cholesterol homeostasis, and autophagy, underscoring their biological relevance in EC pathobiology.
conclusionThis study provides the first comprehensive analysis of LDAGs in EC, establishing robust prognostic and diagnostic gene signatures with strong biological relevance. These signatures support a metabolism-driven framework for EC classification and may offer potential clinical utility in early detection, risk stratification, and personalized treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.